Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2006

View Archived Issues

Recent GE patent discloses novel diagnostic agents

Novel therapeutic agents for nephrotoxicity developed at Hiroshima University

Recent patents describe novel therapeutic agents for psychosis, depression, sleep disorders, etc.

New antiviral agents disclosed in recent patent literature

Suven Life Sciences and Lilly to identify GPCR modulators for CNS disorders

Sankyo and Ajinomoto sign license agreement for diabetes compound AJD-101

Sanofi-aventis extends research collaboration with ImmunoGen

Exelixis submits IND for XL-228

Dyax receives FDA guidance on BLA pathway for DX-88

International Trade Commission rules in Roche's favor for Mircera

Ark files response to EMEA for Cerepro

Aktiv-Dry awarded grant to develop inhalable nicotine vaccine

ACE-393 vaccine against C. jejuni begins phase I

ADX-10059 begins phase II program

Pluristem awarded Israeli grant for stem cell product PLX-1

Preliminary results from phase I study of RAV-12 in adenocarcinomas

Tecadenoson protective against myocardial stunning

Cardioprotective effects of eNOS enhancement

Positive phase II data reported for NV1FGF in critical limb ischemia

Promising efficacy for a novel ragweed immunotherapy vaccine

Preliminary evidence for bronchodilating activity of TPI-1020

Evaluation of ACZ-885 in healthy subjects and mild asthmatics

GSK reports on new LRH-1 agonist for therapeutic assessment in cardiovascular disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.